Cargando…

Zoledronic acid and thymosin α1 elicit antitumor immunity against prostate cancer by enhancing tumor inflammation and cytotoxic T cells

BACKGROUND: Advanced or metastatic prostate cancer (PCa) is still an incurable malignancy with high lethality and a poor prognosis. Despite the remarkable success of immunotherapy against many types of cancer, most patients with PCa receive minimal benefit from current immunotherapeutic strategies,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Sheng, Huang, Maohua, Chen, Minfeng, Sun, Zhiting, Jiao, Yubo, Ye, Geni, Pan, Jinghua, Ye, Wencai, Zhao, Jianfu, Zhang, Dongmei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10277537/ https://www.ncbi.nlm.nih.gov/pubmed/37295817 http://dx.doi.org/10.1136/jitc-2022-006381

Ejemplares similares

Colocalized targeting of TGF-β and PD-L1 by bintrafusp alfa elicits distinct antitumor responses
por: Lan, Yan, et al.
Publicado: (2022)

Combination of vasculature targeting, hypofractionated radiotherapy, and immune checkpoint inhibitor elicits potent antitumor immune response and blocks tumor progression
por: Pierini, Stefano, et al.
Publicado: (2021)

1α,25(OH)(2)D(3) reverses exhaustion and enhances antitumor immunity of human cytotoxic T cells
por: Li, Peng, et al.
Publicado: (2022)

In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis
por: Kim, Seohyun, et al.
Publicado: (2021)

Vδ2 T cells are associated with favorable clinical outcomes in patients with bladder cancer and their tumor reactivity can be boosted by BCG and zoledronate treatments
por: Nguyen, Sylvain, et al.
Publicado: (2022)

Hyperbaric oxygen facilitates teniposide-induced cGAS-STING activation to enhance the antitumor efficacy of PD-1 antibody in HCC
por: Li, Kun, et al.
Publicado: (2022)

CD73 and PD-L1 dual blockade amplifies antitumor efficacy of SBRT in murine PDAC models
por: Ye, Jian, et al.
Publicado: (2023)

Platelets subvert antitumor efficacy of T cell-recruiting bispecific antibodies
por: Lutz, Martina Svenja, et al.
Publicado: (2022)

Metformin generates profound alterations in systemic and tumor immunity with associated antitumor effects
por: Veeramachaneni, Ratna, et al.
Publicado: (2021)

Toll-like receptor 7/8 agonist R848 alters the immune tumor microenvironment and enhances SBRT-induced antitumor efficacy in murine models of pancreatic cancer
por: Ye, Jian, et al.
Publicado: (2022)

Antitumor efficacy of (90)Y-NM600 targeted radionuclide therapy and PD-1 blockade is limited by regulatory T cells in murine prostate tumors
por: Potluri, Hemanth K, et al.
Publicado: (2022)

Synergizing sunitinib and radiofrequency ablation to treat hepatocellular cancer by triggering the antitumor immune response
por: Qi, Xiaoqiang, et al.
Publicado: (2020)

In pancreatic cancer, chemotherapy increases antitumor responses to tumor-associated antigens and potentiates DNA vaccination
por: Mandili, Giorgia, et al.
Publicado: (2020)

Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma
por: Barsoumian, Hampartsoum B, et al.
Publicado: (2020)

NKTR-255, a novel polymer-conjugated rhIL-15 with potent antitumor efficacy
por: Miyazaki, Takahiro, et al.
Publicado: (2021)

L-5-hydroxytryptophan promotes antitumor immunity by inhibiting PD-L1 inducible expression
por: Huang, Jing, et al.
Publicado: (2022)

Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study
por: Oliva, Marc, et al.
Publicado: (2021)

Synergistic antitumor activity of pan-PI3K inhibition and immune checkpoint blockade in bladder cancer
por: Zhu, Shaoming, et al.
Publicado: (2021)

Antitumor immunity as the basis for durable disease-free treatment-free survival in patients with metastatic urothelial cancer
por: Anker, Jonathan, et al.
Publicado: (2023)

Elicitation of stem-like CD8(+) T cell responses via lymph node-targeted chemoimmunotherapy evokes systemic tumor control
por: Manspeaker, Margaret P, et al.
Publicado: (2022)

CCR5 blockade inflames antitumor immunity in BAP1-mutant clear cell renal cell carcinoma
por: Zhou, Quan, et al.
Publicado: (2020)

Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody
por: Park, Jeong A, et al.
Publicado: (2023)

Combination treatment with radiotherapy and a novel oxidative phosphorylation inhibitor overcomes PD-1 resistance and enhances antitumor immunity
por: Chen, Dawei, et al.
Publicado: (2020)

A new oncolytic Vaccinia virus augments antitumor immune responses to prevent tumor recurrence and metastasis after surgery
por: Ahmed, Jahangir, et al.
Publicado: (2020)

Exosomes derived from γδ-T cells synergize with radiotherapy and preserve antitumor activities against nasopharyngeal carcinoma in immunosuppressive microenvironment
por: Wang, Xiwei, et al.
Publicado: (2022)

Targeting of Nrf2 improves antitumoral responses by human NK cells, TIL and CAR T cells during oxidative stress
por: Renken, Stefanie, et al.
Publicado: (2022)

BND-22, a first-in-class humanized ILT2-blocking antibody, promotes antitumor immunity and tumor regression
por: Mandel, Ilana, et al.
Publicado: (2022)

Systemic inflammation shapes clinical outcomes in response to immune checkpoint blockade treatment: moving toward optimizing antitumor immunity
por: Zheng, Ming
Publicado: (2023)

Antitumor activity of the investigational B7-H3 antibody-drug conjugate, vobramitamab duocarmazine, in preclinical models of neuroblastoma
por: Brignole, Chiara, et al.
Publicado: (2023)

A biologic-device combination product delivering tumor-derived antigens elicits immunogenic cell death-associated immune responses against glioblastoma
por: Cultrara, Christopher, et al.
Publicado: (2023)

Rationalized inhibition of mixed lineage kinase 3 and CD70 enhances life span and antitumor efficacy of CD8(+) T cells
por: Kumar, Sandeep, et al.
Publicado: (2020)

Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity
por: Chen, Shih-Hsun, et al.
Publicado: (2021)

Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity
por: Abe, Shinya, et al.
Publicado: (2022)

Antitumor efficacy of combined CTLA4/PD-1 blockade without intestinal inflammation is achieved by elimination of FcγR interactions
por: Bauché, David, et al.
Publicado: (2020)

Simultaneous inhibition of CXCR1/2, TGF-β, and PD-L1 remodels the tumor and its microenvironment to drive antitumor immunity
por: Horn, Lucas A, et al.
Publicado: (2020)

ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma
por: Sheng, Hailong, et al.
Publicado: (2020)

Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages
por: Ou, Da-Liang, et al.
Publicado: (2021)

Selective IL-1 activity on CD8(+) T cells empowers antitumor immunity and synergizes with neovasculature-targeted TNF for full tumor eradication
por: Van Den Eeckhout, Bram, et al.
Publicado: (2021)

Inhibition of integrin αvβ6 sparks T-cell antitumor response and enhances immune checkpoint blockade therapy in colorectal cancer
por: Busenhart, Philipp, et al.
Publicado: (2022)

Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model
por: Lau, Sai Ping, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_un0dtgo5o9cgmdl2it0pnornfh